Lack of Benefit of Fluvoxamine for COVID-19

JAMA. 2023 Jan 24;329(4):291-292. doi: 10.1001/jama.2022.23954.
No abstract available

Publication types

  • Editorial
  • Comment

MeSH terms

  • COVID-19 Drug Treatment*
  • COVID-19* / therapy
  • Fluvoxamine* / therapeutic use
  • Humans

Substances

  • Fluvoxamine